


























































Combining PARP Inhibition with Platinum, Ruthenium or
Gold Complexes for Cancer Therapy
Nur Aininie Yusoh,[a] Haslina Ahmad,*[a, b] and Martin R. Gill*[c]
Platinum drugs are heavily used first-line chemotherapeutic
agents for many solid tumours and have stimulated substantial
interest in the biological activity of DNA-binding metal
complexes. These complexes generate DNA lesions which
trigger the activation of DNA damage response (DDR) pathways
that are essential to maintain genomic integrity. Cancer cells
exploit this intrinsic DNA repair network to counteract many
types of chemotherapies. Now, advances in the molecular
biology of cancer has paved the way for the combination of
DDR inhibitors such as poly (ADP-ribose) polymerase (PARP)
inhibitors (PARPi) and agents that induce high levels of DNA
replication stress or single-strand break damage for synergistic
cancer cell killing. In this review, we summarise early-stage,
preclinical and clinical findings exploring platinum and emerg-
ing ruthenium anti-cancer complexes alongside PARPi in
combination therapy for cancer and also describe emerging
work on the ability of ruthenium and gold complexes to directly
inhibit PARP activity.
1. Introduction
Cancer remains one of the primary causes of death with a high
number of global incidences reported annually. For example, in
2018, 18.1 million new cancer cases and 9.6 million cancer-
related deaths were reported.[1,2] It is predicted that these
numbers will rise within the next two decades. Currently, the
routine methods for cancer treatment are surgical resection or
radiotherapy alongside periods of chemotherapy.[3] Despite
having a high success rate, the efficacy of these strategies is
limited by various factors such as the mass of the tumour to be
removed, the stage of tumour progression, the availability (and
affordability) of radiotherapy, the occurrence of metastatic
tumours and the patient’s health status.[4] As a result, chemo-
therapy remains the most common and realistic option for
cancer treatment.
Rational combination therapies of drugs that act on multi-
ple targets and pathways are being sought to overcome the
limited clinical options available within conventional
chemotherapy.[5,6] If such a drug combination results in
additivity or synergy (a total effect greater than the sum of the
individual effects of each drug), this has the distinct advantage
that lower therapeutic doses of each individual drug can be
used compared to each drug administered as a single-agent.[7–9]
Furthermore, considering the heterogenous nature of many
cancers, drug combinations have potential in reducing the
emergence of drug resistance and chance of relapse.[10,11]
Although a drug combination can give synergistic or additive
interactions in cancer cells, the combination needs to have a
high level of selectivity or large therapeutic index (TI), which is
typically referred to toxicity to cancer cells over normal cells.
Finally, in developing combinations of several chemotherapeu-
tic agents, overlapping toxicity needs to be considered,
especially with regard to the drug doses and scheduling.[12]
Cellular DNA is constantly being subjected to various
endogenous and environmental damages. If the damage
burden is high, this can interfere with fundamental cellular
processes and cells will ultimately undergo cell death. There-
fore, cells have evolved numerous DNA damage response (DDR)
signalling networks to ensure genomic stability and to sustain
continuous cellular progression and growth.[13] Combined with
their high rate of replication and inherent genomic instability,
DDR defects are one of the traditional hallmarks of cancer.[14]
The subsequent development of highly specific DDR inhibitors
along with the concept of synthetic lethality has led to a
paradigm shift in small molecule-based cancer therapy.[15]
Arguably the most successful example of this are inhibitors of
poly (ADP-ribose) polymerase (PARP), one of the key DNA repair
enzymes in DDR signalling pathways.[16] PARPs have become
the rational targets in anti-cancer drug research for the
development of new drugs particularly for ovarian and breast
cancers with defective breast cancer susceptibility gene
(BRCA).[17–19] Several PARP inhibitors (PARPi) have progressed to
clinical trials, and the PARPi olaparib (Lynparza®) has been
approved for clinical treatment of BRCA-mutated HER2-negative
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metastatic breast cancer (2018), gBRCAm metastatic pancreatic
cancer (2019) and maintenance of BRCA-mutated (gBRCAm or
sBRCAm) advanced epithelial ovarian cancers (2018).
While improved therapeutic response to PARP inhibition in
BRCA1/2 mutated-cancers has been shown, PARPi treatment
inherently exerts limited efficacy in the treatment of cancers
without homologous recombination (HR) deficiency.[13] Consid-
ering BRCA-deficient cancers are a relatively small subset of
total cases, chemical strategies to extend the use of PARPi to a
wider range of cancers are under investigation.[20] Numerous
studies in early-stage, preclinical and clinical studies have now
been conducted to examine a wider use of PARPi in combina-
tion therapy alongside various DNA-damaging therapeutics in
BRCA1/2-proficient cancers.[21,22] This aims to take advantage of
greater understanding of DDR signalling in response to DNA
damage and utilise the benefits that combination therapy
offers. The fact several PARPi are FDA-approved then makes this
research clinically translatable.
With the discovery of the platinum-based drug cisplatin by
Barnett Rosenberg and co-workers in 1960, a milestone in the
history of metal-based complexes in treating cancers was
witnessed.[23] Briefly, cisplatin induces platinum-DNA adducts
that cause blockage of replication fork progression, ultimately
resulting in unrepairable DNA damage in the form of cytotoxic
DNA double-strand breaks (DSBs).[24,25] Based on the success of
cisplatin, inorganic medicinal chemists have since examined
alternative transition metal centres such as ruthenium, palla-
dium or rhodium to design complexes which target highly
proliferative cancerous cells with improved therapeutic indices
compared to cisplatin.[26,27] A wide range of metal-based
complexes have been studied as single agents towards cancer
cell lines and their efficacy, mechanism of actions and, in some
cases, toxicity have been elucidated.[28–30] However, as is the
case for the majority of anti-cancer drugs, treatment with a
single agent may not lead to sufficient tumour suppression to
improve disease outcome or patient survival.[11,13]
In this review, we discuss the various ongoing and
completed studies that are examining metal-based complexes
for cancer therapy, with a particular focus on the rational
combination of DNA-targeting complexes alongside PARPi, with
the aim of achieving additive or supra-additive (synergistic)
cancer cell killing, leaving non-malignant cells unharmed and
ultimately improving disease outcomes.
2. Metal-Based Complexes as DNA-Damaging
Agents
Inhibiting DNA synthesis remains one of the central strategies
in cancer therapy.[31] This is based on the principles that cancer
cells possess higher proliferation rates than the majority of
normal cells and are more sensitive to certain forms of DNA
damage due to their inherent genomic instability.[22,32] Typically,
the anti-cancer activities of newly found or synthesised
compounds are explored by determining DNA-drug interactions
in cell-free conditions.[33] In cells, these agents generate DNA
damage by several mechanisms such as modifying the chemical
structure of DNA bases, the generation of DNA crosslinks or
adducts, replication fork stalling, or oxidative stress, all of which
might potentially lead to DNA damage and ultimately cell death
if damage persists.[34]
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2.1. Platinum metal-based complexes
Platinum metal-based drugs have become the standard first-
line chemotherapy for solid tumours and are largely employed
in chemotherapy regimens (Figure 1).[35,36] Among them, cispla-
tin (cis-diamminedichloroplatinum(II)) was the first metal-che-
motherapeutic approved in 1978 and is, to date, part of the
standard drug-used in chemotherapy against a number of
cancer types, including head and neck, testicular, cervical,
oesophageal, ovarian and small cell lung cancers.[25] Cisplatin
induces inter- and intra-strand platinum-DNA crosslinks result-
ing in blockage of replication fork progression. This damage
does not necessarily lead to immediate cytotoxic impact, but
rather impacts cell-cycle progression and induces cell-cycle
arrest. However, if stalled forks cannot be restarted, the
resultant DSB DNA damage generated by replication fork
collapse then leads to mitotic catastrophe and/or apoptosis.[35]
After the breakthrough of cisplatin, the second- and third-
generation cisplatin analogues, carboplatin (cis-diammine(1,1-
cyclobutanecarboxylato) platinum(II)) and oxaliplatin (1R,2R-
diaminocyclohexane oxalatoplatinum(II)) were developed to
reduce toxicity to tissues or organs, improve chemical stability
and expand the scope of activity of these platinum
compounds.[37,38] Both agents successfully passed phase III
clinical trials and are now FDA-approved anti-cancer drugs.
Likewise, they react with DNA forming platinum-induced intra-
and inter-strand crosslinks and were proven effective in various
cancers with reduced toxicity compared to cisplatin.[23,39]
Despite their clinical success, these platinum drugs possess
inherent clinical drawbacks such as high general toxicity even
when administered at lower doses, and poor selectivity against
normal cells leading to severe adverse effects including
myelosuppression, nephrotoxicity and neurotoxicity.[25] This
class of drug has also proven to be ineffective in patients with
intrinsic or acquired chemoresistance.[40–42] These well-estab-
lished limits can significantly reduce their efficacy during
treatment or even render them ineffective.[43,44] Galuzzi et al.
classified the mechanisms of resistance towards cisplatin into
four main categories: (a) “Pre-target resistance”, by reducing the
likelihood of cisplatin cellular accumulation, thereby preventing
the interaction between cisplatin and DNA. This includes
reducing drug uptake and increasing drug efflux and drug
detoxification. (b) “On-target resistance”, by reversing the
effects of cisplatin-induced DNA adducts. (c) “Post-target
resistance”, by enhancing DNA repair capability that is activated
following cisplatin-induced DNA lesions. (d) “Off-target resist-
ance”, by molecular mechanisms which are not directly
associated with cisplatin induced signals but enable cells to
circumvent cisplatin-induced cell death.[45,46] These clinical draw-
backs in platinum drugs have encouraged substantial efforts to
replace them with suitable alternatives by using other transition
metal complexes with higher efficacy and lower systemic
toxicities – i. e. improved therapeutic windows – in tumour
treatment.[47–50]
2.2. Ruthenium metal-based complexes
Ruthenium metal complexes have attracted a great amount of
interest in the last two decades for their anti-cancer properties.
Initially, complexes were designed to coordinately bind DNA via
the ruthenium metal centre with similar substitution kinetics to
platinum complexes but altered potency in vitro and in vivo.[51,52]
In addition to metal centre-based reactivity, the coordinated
ligand(s) can interact with DNA or protein targets through
reversible or covalent binding mechanisms. Ndagi et al. provide
a review describing how incorporating an octahedral ruthenium
metal centre can bring a unique contribution to drug design.[26]
The first three ruthenium-based complexes to successfully
enter phase I clinical investigations were NAMI-A, KP1019 and
NKP1339 (Figure 2). NAMI-A [ImH][trans-RuCl4(DMSO)(Im)]
where Im= imidazole and DMSO=dimethyl sulfoxide was the
first ruthenium complex to enter clinical trials in 2002.[53] Even
though NAMI-A showed low potency in vitro in terms of direct
cytotoxicity on non-small cell lung cancer (NSCLC) cells, it has
effective and strong inhibitory efficacy on lung metastatic
tumour in vivo.[54] Subsequently, KP1019 [indazolium trans-
tetrachlorobis(1H-indazole)ruthenate(III)] entered phase I clinical
trial but failed to undergo further investigation due to its high
hydrophobicity and poor water solubility limiting further clinical
development.[55,56] Hence, to improve the poor water solubility
of KP1019, the derivative NKP1339 with improved aqueous
solubility was developed and is currently undergoing clinical
trials.[57,58] In addition to improved transmembrane absorption
efficiency, NKP1339 demonstrated disease stabilisation in a
phase I study against solid tumours, most remarkably in
patients with gastrointestinal neuroendocrine tumours.[59,60]
Reduced side effects were also noted in trial patients in the
absence of clinical jaundice or other signs or symptoms.[57]
Ruthenium(II) polypyridyl complexes (RPCs) have emerged
as promising drug candidates due to their ability to form non-




2123ChemMedChem 2020, 15, 2121–2135 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH GmbH
Wiley VCH Mittwoch, 25.11.2020


























































covalent (reversible) interactions with DNA.[61,62] DNA binding
properties of these complexes can be tuned via substitution or
modification of the ligand(s) around the Ru(II) centre.[63] Many
RPCs are phosphorescent and thus possess an imaging
diagnostic capability that can be used to verify intracellular
DNA or other biomolecule targeting.[62] Finally, numerous RPCs
act as photosensitizers for photodynamic therapy (PDT).[64,65] In
this latter capacity, the RPC photosensitizer TLD1443 [Ru
(dmb)2(LL’)]
2+ where dmb=4,4’-dimethyl-2,2’-bipyridine and
LL’=2-((2’,2’’:5’’,2’’‘-terthiophene)-imidazo[4,5-f][1,10]phenan-
throline) was shown to significantly improve the efficacy of PDT
and is currently undergoing phase II trials for bladder cancer
patients (Figure 3).[66]
Other notable examples include the ruthenium(II)-arene
complexes which have attracted substantial interest in recent
years following encouraging anti-metastatic, anti-angiogenic
and anti-tumoral properties in vivo.[67,68] For example, RAPTA-T
Ru(η6-toluene)-(PTA)Cl2 and RAPTA-C [Ru(η
6-p-cymene)Cl2(PTA)]
where PTA=1,3,5-triaza-7-phosphaadamantane. Most encour-
agingly, RAPTA-C appears to be well tolerated in vivo as
determined by the high doses that can be tolerated in animals
in comparison to platinum drugs. Similar to observations made
on NAMI-A, RAPTA-C showed limited direct cytotoxicity on
cancer cells in vitro; however, it exhibited strong anti-
metastatic behaviour in vivo.
Encouragingly, clinical findings demonstrated that the two
ruthenium complexes of KP1019 and NKP1339 resulted in
disease stabilisation and no severe adverse effects were
noted.[55,57] Compared to platinum drugs, they showed various
clinical benefits including low general toxicity, greater tumour
selectivity and importantly, potent efficacy on platinum-
resistant tumours was seen in a preclinical model.[66,69] However,
despite these major benefits, ruthenium complexes as single
agents or monotherapy may not lead to sufficient tumour
suppression, and the doses required for cancer cell killing are
often very high. As discussed above, drug combination
therapies are common in clinical practice and so using these
therapeutic strategies to improve clinical response to ruthe-
nium-based complexes represents a promising line of research.
3. DNA Damage Response (DDR) Signalling
Pathways
3.1. DNA repair mechanisms
DNA lesions at the base pair level such as alkylated nucleo-
bases, single-strand breaks (SSBs) or platinum-associated intra-
and inter-strand crosslinks are repaired by base excision repair
(BER), nucleotide-excision repair (NER) and mismatch repair
(MMR) pathways. Meanwhile large scale DNA lesions, such as
DSBs and clustered damages require either homologous
recombination (HR) repair or the non-homologous end joining
(NHEJ) repair pathways.[13,42]
Small DNA adducts are mainly repaired by the BER pathway
which requires specific DNA glycosylase to recognise mis-
matched base pairs in double-stranded DNA and cleave the N-
glycosyl bond between the deoxyribose sugar and the nitro-
genous base of the affected nucleotide, generating an abasic
site.[70] Apurinic/apyrimidinic (AP) endonucleases then create a
nick in the phosphodiester backbone, and the resulting gap is
filled by DNA polymerase, which is then sealed by DNA ligase.
Another alternative DNA repair pathway involved in SSB repair
that is functionally related to BER is the NER pathway with the
major difference between these pathways is the size of damage
that can be recognised.[42] While BER detects non-bulky DNA
lesions and corrects damaged bases that are removed by a
specific glycosylase, NER is particularly important to repair bulky
DNA adducts. The major protein involved in NER includes
excision repair cross-complementation group 1 factor (ERCC1)
which with ERCC4, forms a structure-specific heterodimer
complex of XPF-ERCC1 endonuclease. This endonuclease
cleaves the damaged strand on both sides of the lesion, and
the oligonucleotide containing the lesion is excised. Finally,
DNA polymerase fills the resulting gap by the process of HR.
Most DSBs repair mechanisms are mediated by HR repair
pathway with BRCA1/2 proteins serving as the critical compo-
nents in the repair process.[71] A crucial role of BRCA1/2 is
binding the RAD51 protein, forming a complex on the DNA
strand. Following this complex formation, the proteins that
initiate the repair process are recruited to the damaged site.
This process also involves a second, homologous intact strand
of template DNA to allow for the precise restoration of the
original DNA sequence.
3.2. DNA damage response (DDR) signalling
The DNA damage response (DDR) signalling network is an
intricate signal transduction cascade that prevents cell-cycle
continuation to allow the complete removal of DNA lesions
prior to cell division (Figure 4).[72,73] Three major DNA-damage
checkpoints have been described, located at G1/S, intra-S, and
G2/M phases of the cell-cycle. The key signal transducers of
downstream DDR pathways are ataxia telangiectasia mutated
(ATM) and ataxia telangiectasia and Rad3 related (ATR) protein




2124ChemMedChem 2020, 15, 2121–2135 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH GmbH
Wiley VCH Mittwoch, 25.11.2020


























































activated by the MRN complex, a DSB-recognising protein
which phosphorylates a high number of DNA damage mediator
proteins carrying the consensus sequence of ATM. This triggers
the activation of downstream cell-cycle regulator proteins, such
as checkpoint kinase 2 (Chk2), which in turn activates down-
stream effector proteins that leads to cell-cycle arrest and the
activation of DNA repair pathways. This pathway also triggers
the activation of p53, a tumour suppressor protein which
decides cellular fate depending on repair efficiency or the level
of DNA damage. When the level of damage is high, the intrinsic
pathway of apoptosis is triggered, resulting cell death. Lesions
due to stalled replication forks induce SSBs or DNA replication
stress. In these cases, replication protein A (RPA) binds to the
SSB and recruits ATR kinase via its association with ATR
interacting protein (ATRIP). Finally, this activates the down-
stream regulator protein, checkpoint kinase 1 (Chk1), which in
turn activates downstream effector proteins.
3.3. PARP: a key DDR enzyme family
PARPs are a family of 17 enzymes encoded by genes that
mediate several cellular processes, including DNA damage
repair, maintenance of genomic stability and regulation of
transcriptional control.[74,75] The role of PARP in DDR signalling
was first reported in 1979, where PARP activity was found to
increase after administration of chemo or radiotherapy.[76] PARP
activation is now known to be an early response to SSB
repair.[77] Alongside its role in SSB repair, PARP also mediates
replication restart following replication fork stalling to ensure
faithful genome duplication.[78,79] PARP activation has been
implicated to increased activities of BER and NER pathways, the
predominant SSBs repair pathways in cells with a fully func-
tional DDR capacity.[80] At the molecular level, PARP is recruited
and binds to SSBs through its highly conserved N-terminal zinc
finger domains, which in turn activates its C-terminal motif
leading to the hydrolyzation of NAD+ . This generates long
chains of ADP-ribose monomers (PARylation) and subsequently
initiates the repair process by actively recruiting other repair
proteins, including X-ray repair cross complementing protein 1
(XRCC1), DNA polymerase β (Polβ) and DNA ligase III (LIG3).[81]
Deletion of the PARP gene in experimental cell models along-
side high levels of SSBs resulted in the accumulation of DSBs,
cell-cycle arrest and/or cell death.[82,83]
3.4. PARP inhibitors
First-generation PARPi were developed over 40 years ago and
were simple analogues of nicotinamide such as 3-substituted
benzamides (e.g. 3-aminobenzamide (3-AB); Figure 5).[84]
Bernges and Zeller reported that by inhibiting PARP activity
with 3-AB (PARP1 half-inhibitory concentration, IC50,=10 μM),
the alkylating agent carmustine exhibited increased cytotoxicity
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in ovarian cancer cell lines.[85] Studies conducted in pancreatic
cancer cells by Jacob et al. similarly reported that inhibition of
PARP activity using 3-AB leads to improved responses to
standard gemcitabine regimen.[86] Although 3-AB showed
encouraging results in sensitising cells to genotoxic agents,
high dosages were required in preclinical models. Second-
generation PARPi were subsequently developed in the 1990s
based on quinazoline analogues (e. g. PJ34 and NU1025;
Figure 5). These agents showed more efficient targeting and
substantially improved activity in inhibiting purified human
PARP1 enzyme than the early-generation PARPi 3-AB (PARP1
IC50s=20 and 400 nM for PJ34 and NU1025, respectively).
[87]
The breakthrough in this area was the discovery that PARPi
act as a potent therapeutic agent in cancers harbouring HR
repair defects, such as those with BRCA mutations.[12,88–90] The
basis for this synthetic lethality is that in HR-deficient cells, DSBs
generated by PARP inhibition cannot be repaired leading to
mitotic catastrophe and/or apoptosis. Cells with normal HR
function are able to repair PARPi-induced DSB damage,
resulting in synthetic lethality exclusively in HR-deficient cells.
Shortly after this realisation, further development of the third-
generation PARPi based on benzimidazoles led to more potent
PARPi which rapidly entered clinical trials. Prominent examples
include olaparib (AZD2281), rucaparib (AGO14699), niraparib
(MK4827), veliparib (ABT888), and talazoparib (BMN673) (Fig-
ure 6).[16] In 2015, olaparib (Lynparza®) and rucaparib (Rubraca®)
have passed phase III clinical trials and are FDA-approved for
the treatment of advanced ovarian cancer patients with
mutations in the germline BRCA1/2 genes.[91] Niraparib (Zejula®)
was additionally approved for the maintenance treatment of
recurrent and platinum-sensitive ovarian cancer patients. Most
recently, talazoparib (Talzenna®) was approved for advanced
and metastatic breast cancer patients.
Cellular investigations using these third-generation inhib-
itors led to the discovery that PARPi can also trap PARP
enzymes (termed as “PARP trapping”) at the damage site.[92–94]
Trapped PARP-DNA complexes have been suggested to be
more cytotoxic than unrepaired SSBs caused by PARP
inactivation.[95] As a result, PARPi are often classed by their PARP
trapping potency as well as PARP inhibitory effects.
Although breast and ovarian cancers with mutations in
BRCA1/2 demonstrate exquisite sensitivity to PARPi, these
cancers represent a relatively small subset of cancers.[96]
However, niraparib (Zejula®) also showed significant benefit in
patients with functional HR repair capability, indicating that
there are likely potential biomarkers and mechanisms that may
provide sensitivity towards PARP inhibition in addition to HR
pathway genes.[12]
Figure 5. First-generation PARP inhibitor, 3-AB and second-generation PARP
inhibitors, PJ34 and NU1025. Nicotinamide/benzamide pharmacophore
group shown in blue.
Figure 6. Structures of clinical and FDA-approved PARP inhibitors with
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3.5. Alterations in PARP: a mechanism of platinum drug
resistance?
The activity of PARP in DNA repair has been shown to
counteract many types of DNA damaging chemotherapies and
thus is crucial for the emergence of resistance during prolonged
cancer treatment.[22] Interestingly, overexpression of PARP has
been noted in several cancer cell lines compared to their
normal counterparts.[97] The role of PARP hyperactivation in
therapeutic resistance to cisplatin in the majority of advanced
tumours and human cisplatin-resistant cancer cells has been
described in detail by Michels et al.[98] For example, NSCLC cells
with poor responses to cisplatin treatment exhibited high
expression level of PARP.[99] Constitutive activity of PARP is also
essential for treatment resistance and disease progression in
glioblastoma-initiating cells.[100,101] A prominent example is
provided by mechanistic studies by Lavrik et al. where the
authors found that PARP is immediately activated in cells
following the addition of platinum drugs. When PARP auto-
PARylates, BER pathway proteins are recruited to the DNA
damage sites. While PARP is stabilised on the DNA strand, the
recruitment of other BER proteins is hampered, hindering DNA
repair processes.[102]
In addition to the role of PARP hyperactivation in platinum
resistance, Amable et al. showed the association between high
levels of ERCC1 expression and cisplatin resistance in cancer
therapy.[40] The basis for this is that increased ERCC1 expression
levels is associated with increased NER repair capacity which
effectively reverse the effects of platinum-DNA adducts. These
studies included data from ovarian, cervical, lung, liver, and
gastric cancers, indicating that high level of ERCC1 expression
could be an early potential indicator in determining cellular
platinum resistance and disease progression.[103] On the other
hand, testicular, primary gastric, and lung cancer that have low
levels of ERCC1-XPF expression have been shown to be highly
responsive to platinum drugs.[42] In these cancers, improved
survival of patients treated with platinum drugs was observed
due to the reduced cells capability to repair DNA lesions,
eliciting the importance of ERCC1 expression levels in treatment
resistance.
Considering the enhancement of DNA repair capability is
one of the major contributions to resistance in cancer cells, it
follows that simultaneous inhibition of PARP activity alongside
DNA-targeting platinum and ruthenium metal complexes could
suppress chemoresistance and in addition to heightening
sensitivity towards these DNA-damaging metal complexes.
4. PARP Combination Therapy: A Promising
Strategy
The rational combination of a DNA-damaging agent alongside a
PARP inhibitor has long been hypothesised to induce syner-
gistic activity.[104,105] More recently, it has also become apparent
that this strategy can expand the use of PARPi to a greater
population of cancer types, independent of BRCA status.[106]
Olaparib, for example, has been shown to synergistically
improve the activity of ionising radiation (IR),[107,108]
gemcitabine,[109] the alkylating agent temozolomide,[110] and
topoisomerase inhibitors such as doxorubicin[111] and
topotecan[110] in various cancers irrespective of their BRCA
status. However, many of the DNA-damaging agents tested
alongside PARPi to date are potent cytotoxics and generate
high levels of DSB damage; two features which may have
unfavourable mechanistic and toxicity overlap with PARPi. In
the following sections, we discuss the early-stage, preclinical
and clinical work of the rational combinations between
platinum and ruthenium metal-based complexes and PARPi for
enhanced cancer therapy, as well as potential applications of
PARPi in combination with cell-cycle inhibitors.
4.1. Combination of cisplatin and 3-AB or PJ34
An early in vitro study showed that the combination of cisplatin
and PARPi 3-AB resulted in enhanced cell-cycle arrest and
apoptosis in cisplatin-resistant ovarian tumour cells.[85] Other
examples assessed the combination of cisplatin with the
second-generation PARPi PJ34. Mechanistic investigations in
triple-negative breast cancer (TNBC) cells revealed that the
synergistic combination was mediated by sustained DNA
damage and inefficient NER repair triggering apoptosis.[112]
Similarly, in lung cancer cells, the combination significantly
increased DNA damage foci, resulting in the loss of clonogenic
potential of these cells and ultimately triggering apoptotic cell
death.[99] PJ34 enhanced the suppressive effects of cisplatin in a
dose-dependent manner in the growth of HepG2 liver cancer
cells, accompanied with increased apoptosis.[113] This combina-
tion was shown to inhibit the growth of HepG2 cell-derived
tumours in nude mice and is one of the earliest in vivo studies
that provided evidence to support this combination strategy.
4.2. Combination of cisplatin and olaparib
The combination of cisplatin and olaparib in a small panel of
lung cancer cell lines found cancer cell killing was achieved
specifically in cells with low ERCC1 expression.[114] Mechanistic
studies indicated that this combination leads to sustained DSBs,
prolonged G2/M cell-cycle arrest and the activation of Chk1
signalling with a significantly marked increase in apoptosis. In
cervical cancer cells, the combination of cisplatin and olaparib
synergised with a significant anti-proliferative effect and loss in
clonogenic survival compared to single agents alone.[115] These
findings were accompanied with increased DSB levels and
apoptotic cell death (Figure 7a–c). Further mechanistic inves-
tigations revealed that olaparib disrupts the localisation of the
BER effector proteins XRCC1 and NHEJ proteins Ku80 and
XRCC4 that modulate DNA repair efficiency in cells (Figure 7d).
A phase I trial evaluating this combination showed improved
tolerability and promising anti-tumoral activity in patients with
advanced ovarian, breast and other solid tumours, particularly
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NCT00782574).[116] At the end of the study, 41% of the patients
with measurable disease achieved overall objective response
rate. Among patients who had ovarian and breast cancer with
mutations in BRCA1/2, the overall objective response rate
achieved were 43% and 71%, respectively.
4.3. Combination of carboplatin and olaparib
The concomitant administration of carboplatin and olaparib has
been shown to induce lethality in a synergistic manner in MDA-
MB-231 and CAL51 TNBC cell lines.[117] This study included the
phosphatidylinositol 3-kinase (PI3K) inhibitor BKM12 as the
P13K intracellular signalling pathway has become one of the
molecular targets for cancer therapy due to its role in regulating
the essential cellular functions, including metabolism, prolifer-
ation, cell survival, growth and angiogenesis.[118] In addition to
this, TNBC is characterised by extensive copy number alter-
ations that promotes PI3K pathway activation with deficiencies
in DNA damage HR repair. Drug synergy was observed in both
TNBC cell lines with a clear impact on cell-cycle progression.
Western blotting and immunofluorescence studies indicated
that this combination exerted its cytotoxicity via DNA damage,
enhancing NHEJ repair while inhibiting HR repair. Another
notable example includes a study on the combination of
carboplatin and olaparib conducted in high-grade serous
ovarian cancer cells (HGSOC).[119] Synergy was observed in both
BRCA1/2-proficient and -deficient cell lines, indicating that the
therapeutic benefits of this combination is independent of
BRCA status (Figure 8a). Mechanistic studies revealed that the
synergy observed in BRCA-deficient UWB1.289 cell lines were
due to increased DNA DSBs (Figure 8b). This combination was
also found to greatly inhibit the tumour growth of BRCA2-
mutated ovarian serous carcinoma.[120]
In a phase II clinical investigation, the combination of
olaparib with carboplatin-paclitaxel was investigated in high-
grade and recurrent ovarian cancer patients with sensitivity to
platinum regimens and deficiency in BRCA genes (ClinicalTrials.-
gov identifier: NCT01081951).[121] The combination significantly
improved the chances of progression-free survival; 9.6 months
to 12.2 months in these patients, with the greatest clinical
benefit observed in BRCA-mutated patients. Importantly, an
acceptable and manageable tolerability profile was reported
with 12 of 81 patients (15%) in the combination treatment
group experienced serious adverse events compared to 16 of
75 patients (21%) in the single-agent treatment group.
Collectively, this combination is considered safer and feasible
than monotherapy especially for high-grade and recurrent
ovarian cancer patients.
Figure 7. (a) Cell viability of cervical cancer SiHa and ME180 cells upon treatments with cisplatin and olaparib alone or in combination, as determined by MTT
assay. (b) Clonogenic survival of cervical cancer cells upon treatments with cisplatin, olaparib or both. (c) Quantification of the percentage of cells showing
γH2A.X+53BP1+cells as DNA damage marker upon treatments with the respective mentioned groups. (d) Quantification of relative co-localisation of XRCC4/
KU80/XRCC4 foci and γH2A.X foci in the respective mentioned groups. Figure adapted from reference 115 under the terms of the Creative Commons
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4.4. Combination of carboplatin/cisplatin and veliparib
Despite showing limited single-agent cytotoxicity, in vitro
studies found the PARPi veliparib selectively potentiated the
effects of cisplatin and carboplatin in five of nine small cell lung
cancer (SCLC) cell lines (Figure 8c).[122] Moreover, the combina-
tion of veliparib and cisplatin showed greater tumour growth
inhibition compared to single-agent treatment groups in a lung
cancer xenograft model (Figure 8d). In addition to this early
study, a phase I trial involving the combination of carboplatin
and veliparib in advanced ovarian cancer patients was con-
ducted (Clinicaltrials.gov identifier: NCT01063816).[123] Overall,
treatment with this combination was efficient and associated
with an overall response rate of 49.2%. In a recent phase III trial
in 2018 involving six hundred and thirty-four TNBC patients, the
combination of carboplatin and veliparib with paclitaxel
significantly improved the proportion of TNBC patients who
achieved a pathological complete response compared to single
agents, although the overall survival or progression free survival
or was not conclusive (ClinicalTrials.gov identifier:
NCT02032277).[124] It was also reported that increased toxicities
following the addition of carboplatin and veliparib was
manageable and the treatment delivery of paclitaxel was not
substantially affected.
4.5. Combining ruthenium-based complexes with PARPi
Ruthenium metal-based complexes have been examined exten-
sively as single agents for their anti-cancer properties.[47]
However, studies into the combination of ruthenium complexes
with other compounds are uncommon due to several uncertain
factors, including on how to select compounds for combination
and the potential mechanism(s) of drug synergism.[125] Never-
theless, several studies with first-line anti-cancer agents, includ-
ing the combinations of Ru(II) complex/radiation,[126] NAMI-A/
doxorubicin,[127] RAPTA-C/doxorubicin,[67] Ru(II) complex/
doxorubicin,[128] NKP1339/sorafenib,[129] and RAPTA-C/
erlotinib[130] have been explored both in vitro and in vivo.
Moreover, the combination of NAMI-A/gemcitabine has been
clinically investigated in phase I/II trials for NSCLC patients.[131]
Compared to single agents alone, favourable efficacies and
synergistic anti-tumour efficacy with desirable toxicity profiles
were reported. However, studies on the combination of
Figure 8. (a) Cell viability of BRCA-deficient (UWB1.289) and BRCA-proficient (UWB1.289+BRCA1) high grade serous ovarian cancer cells upon treatment with
carboplatin (CPT) and olaparib (OPB) alone or in combination for 72 h, as determined by MTT assay. (b) Quantification of γH2AX foci formation as DNA
damage marker upon treatments with carboplatin, olaparib or both for 72 h. (c) IC50 concentrations of cisplatin alone or in combination with 5 and 50 μmol/L
of veliparib in nine different SCLC cells. (d) The tumour volume of H146 SCLC xenograft model following treatment with cisplatin and veliparib alone or in
combination. Figure (a–b) reprinted (adapted) with permission from reference 119. Copyright 2018 American Chemical Society. Figure (c–d) adapted from
reference 122 under the terms of the Creative Commons Attribution 3.0 Unported Licence (https://creativecommons.org/licenses/by/3.0/). Cancer Medicine
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ruthenium-based complexes with PARPi or other small mole-
cules DDR-targeting agents are a relatively new concept.
Ruthenium(II) metallo-intercalators have been shown to stall
replication fork progression and generate high levels of
replication stress in cancer cells.[132,133] This finding provides
justification for the assessment of this class of complexes
alongside PARPi. Recently, we demonstrated that the combina-
tion of the multi-intercalator [Ru(dppz)2(PIP)]
2+ (or Ru-PIP,
Figure 9a) where dppz=dipyrido[3,2-a:2’,3’-c]phenazine and
PIP=2-(phenyl)-imidazo[4,5-f][1,10]phenanthroline with either
NU1025, a second-generation PARPi, or olaparib showed
synergy in BRCA wild-type TNBC breast cancer cells (Fig-
ure 9b).[134] As the predominantly cytostatic Ru-PIP acts to stalls
replication fork progression without triggering a DSB damage
response,[133] PARPi-mediated replication fork collapse results in
a significant increase in DSBs damage, accompanied by G2/M
cell cycle arrest and cell death via apoptosis. This combination
led to a dramatic increase in the potency of olaparib, where
300-fold greater activity due to the addition of Ru-PIP was
observed by clonogenic survival assay (Figure 9c). Promisingly,
a mild impact on non-malignant NHDF human fibroblast cells
was observed, indicating a potential high tumour selectivity
activity of this combination which merits further investigation
in vivo.
While the combination of ruthenium with PARPi demon-
strated good results, Gill et al. has also showed the potential of
combination with other DDR inhibitors. The concurrent treat-
ment of Ru-PIP with a Chk1 inhibitor, CHIR-124 showed
synergistic apoptosis in HeLa cervical cancer cells, with a
significant increase in DSBs resulting from stalled replication
fork collapse while having minimal impact on non-malignant
HFF human epithelial cells.[133]
As discussed, PARP inhibition in combination therapy has
mainly utilised potent cytotoxic DSB-generating agents that
activate G2/M arrest. It is therefore noteworthy that a cytostatic
replication inhibitor and PARPi can also achieve synergy in
cancer cells.
4.6. Combination of PARPi and cell-cycle inhibitors
Synergy with PARPi is not necessarily limited to DNA-damaging
agents. Although PARPi are active in HR-deficient cancers,
particularly those lacking BRCA1/2, their utility is limited by the
development of resistance which may occur through restora-
tion of HR function.[135] These BRCA-deficient cells rely heavily
on cell-cycle regulators to reverse the effects of PARP inhibition
and become PARPi-resistant cells. As such, the combination of
PARPi and cell-cycle checkpoint inhibitors such as ATR,[136–138]
Chk1,[139] and WEE1[140,141] have recently been investigated in
several different cancers. These combinations demonstrated
enhanced efficacy, especially in overcoming PARPi-resistance
and act to abrogate PARPi-induced G2/M arrest and prevent
DNA damage repair.
Other potential combination partners for PARPi are inhib-
itors of cyclin dependent kinases (CDKs).[142,143] In addition to
playing a crucial role in cell-cycle regulation, CDK1 was found to
Figure 9. (a) Structure of [Ru(dppz)2(PIP)]
2+ or Ru-PIP. (b) Cell viability of
BRCA wild-type TNBC MDA-MB-231 cells following 24 h treatments with Ru-
PIP alone or in combination with PARP inhibitors (olaparib concentrations of
5 or 10 μM and NU1025 concentrations of 25 or 100 μM were used), as
determined by MTT assay. (c) Clonogenic survival of MDA-MB-231 cells upon
24 h treatments with a concentration gradient of olaparib with and without
Ru-PIP (25 μM). Single-agent Ru-PIP has low impact on clonogenic survival at
this concentration (S.F. >95% at 25 μM), indicating it is sensitising TNBC
cells to olaparib. Reprinted (adapted) with permission from reference 134.
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phosphorylate BRCA1, an event essential for efficient BRCA1
focus formation and HR repair.[144] Therefore, CDK inhibition
presents a method to induce a form of BRCA-deficiency, thereby
rendering treated cells sensitive to PARPi. Based upon this
concept, a CDK1 inhibitor was found to sensitise BRCA-
proficient cancers to PARP inhibition in human lung NSCLC
xenografts.[144] Recent work with olaparib and palbociclib (a
CDK4/6 inhibitor, Figure 10a) has demonstrated potent synergy
in ovarian cancer cells overexpressing MYC both in vitro and
in vivo.[145] This combination significantly increased anti-prolifer-
ative effects in vitro and inhibited tumour growth in vivo
compared to single-agent treatment groups (Figure 10b–c).
Mechanistically, this combination induced HR deficiency in a
MYC-dependent manner. In another study, dinaciclib, a CDK1, 2,
5, 9 and 12 inhibitor diminished HR pathway function and
reversed acquired PARPi-resistance in BRCA-proficient and
-deficient TNBC.[146] The combination of veliparib and dinaciclib
against patients with advanced solid tumours who are not
germline BRCA carriers was evaluated in a phase I study. This
found that twenty-four patients (38%) had stable disease as the
best response with nine progression-free (ClinicalTrials.gov
identifier: NCT01434316).[147] These findings show the potential
of using this combination strategy to re-establish PARPi
sensitivity. Bearing in mind many anti-cancer transition metal
complexes achieve potent effects on cell-cycle progression
without generating cytotoxic or genotoxic DNA damage, this
may be a lucrative area for future investigation.
5. Metal Complexes as PARP Inhibitors
In addition to their use in combination therapy alongside
organic PARP inhibitors, the metal complex itself can inhibit
PARP activity. Here, we summarise work that has explored this
emerging concept.
5.1. Ruthenium complex as PARP inhibitors
A small number of studies have explored the ability of
ruthenium complexes to function as PARP inhibitors. Mendes
et al. showed that RAPTA-T and NAMI-A were found to be more
effective than 3-AB in inhibiting purified human PARP1 enzyme
(24 h IC50 concentrations of 28 μM and 18.9 μM for RAPTA-T and
NAMI-A, respectively, compared to 3-AB with IC50 =33 μM).
[148]
An organometallic ruthenium(II) complex, [RuIICp(bipy)(PPh3)]
[CF3SO3] (or TM34) (bipy=2,2’-bipyridine and PPh3 = triphenyl-
phosphine) demonstrated the strongest PARP1 inhibitory
activity reported so far for a ruthenium complex, with a 24 h
IC50 value of 1 μM.
[149]
Finally, Wang et al. suggested that the conjugation of
ruthenium(II) arene moieties to PARPi significantly improved
anti-cancer activity in cancer cells in vitro compared to the
reference compound RAPTA-C (Figure 11).[150] Anincrease in
both cellular ruthenium content and cell-cycle arrest at G1/S
phase were observed following treatment with Ru-PARPi.
Compared to its free ligand, the coordination of PARPi to
ruthenium also led to a more water-soluble species. Further
mechanistic investigations revealed that these ruthenium-PARPi
conjugates have improved PARP inhibitory activity compared to
the free PARPi ligand and possess multi-targeting properties
through DNA binding and transcription inhibition. Encourag-
ingly, a mild effect was observed in non-malignant MRC5
human lung cells, likely due to the lower cellular uptake
observed in these cells.
Figure 10. (a) Structure of palbociclib. (b) Representative images of ovarian
cancer A2780 xenografted tumours isolated from mice following treatments
with olaparib, palbociclib or both. (c) The tumour volume of A2780
xenografted mice in the respective mentioned groups, with the arrow
indicating the starting date of the treatment. Reprinted from EBioMedicine,
43, Yi, J. et al., MYC Status as a Determinant of Synergistic Response to
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5.2. Gold complexes as PARP inhibitors
Strikingly, Mendes et al. also revealed the Au(I) antirheumatic
agent auranofin (Au(2,3,4,6-tetraO-acetyl-1-(thio-kS)-β-D-gluco-
pyranosato)PEt3 where PEt3 = triethylphosphine) and two Au(III)
polypyridyl complexes [Au(phen)Cl2]Cl and [Au(bipy)Cl2]Cl
display low nanomolar IC50 values for PARP1 inhibition (Fig-
ure 12a).[148]
Decreased PARP1 activity is explained by the ability of the
complexes to bind the zinc-finger motif of PARP1, ejecting zinc
and inactivating the enzyme in the process (Figure 12b).[151,152]
Although [Au(phen)Cl2]Cl, [Au(bipy)Cl2]Cl and derivatives display
greater PARP1 inhibitory effects than olaparib and exhibit
cytotoxicity in several cancer cell lines,[153] their specificity
towards BRCA-deficient cancer cells or ability to synergise with
DNA-damaging agents or ionising radiation is unknown at
present. Also of relevance is work by Citta et al., which
described a PARP1 inhibitor coordinated to a Au(III) metal
centre. In addition to showing antiproliferative effects against
human cancer cells, the compound potently and selectively
inhibits PARP1 with respect to the seleno-enzyme thioredoxin
reductase.[154] Preliminary studies of this Au(III) PARPi indicated
promising anti-proliferative activity towards several cancer cell
lines and an additive relationship when explored in combina-
tion with cisplatin.
6. Summary and Outlook
Typified by the platinum drugs and their potential successors in
ruthenium complexes, many metal-based complexes have been
shown to kill cancer cells by interacting with DNA, resulting in
the inhibition of DNA synthesis and/or generation of DNA
damage. However, these single-agent treatments are clinically
limited, particularly in overcoming the ongoing challenge of
drug resistance. The combinations of platinum-based drugs and
PARPi showed remarkable synergy in preclinical work and
mechanistic findings revealed that these synergistic combina-
tions are mainly associated with decreased DNA repair capacity
and associated cell death from the accumulation of double-
strand break damage. Given the impressive clinical findings of
combination therapies that demonstrated improved overall
response rate with manageable toxicity profiles compared to
each agent administered alone, these novel synergistic combi-
nation strategies have potential in improving clinical outcomes
and achieving sufficient tumour suppression. While combina-
Figure 11. Structures of PARPi L1-L3 (as the ruthenium coordinating ligand)
and Ru-PARPi 1–3 (conjugated ruthenium(II) arene complexes). Reprinted
from Journal of Inorganic Biochemistry, 131, Wang, Z. et al., Multi-targeted
organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors
of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity, 47–55,
Copyright 2013, with permission from Elsevier.
Figure 12. (a) Structures of antirheumatic agent, Auranofin and three Au(III)
compounds (Aubipy, Auphen and Au  C  N). (b) Gold finger formation.
Example of the possible binding of Au  C  N with the zinc finger domain of
PARP1, in which two chlorido ligands of Au  C  N have been replaced by two
cysteinato groups. Figure (b) adapted from reference 152 under the terms of
the Creative Commons Attribution 3.0 Unported Licence (https://creative-
commons.org/licenses/by/3.0/). Published by The Royal Society of Chemistry.
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tion therapies of metal-based complexes with DDR inhibitors
are now being evaluated for synergy, further research is
required to fully explore the underlying molecular mechanisms
of synergy between compounds. With the expanding knowl-
edge of the mechanisms of action of metallodrugs, combined
with gained insight into drug synergy, rapid expansion in the
studies on the combinations between metal-based complexes
with DNA repair inhibitors in clinical applications can be
perceived. Although DNA-targeting complexes hold the great-
est promise to synergise with PARPi, it would be fascinating to
examine whether mitochondrial-targeting agents or PDT photo-
sensitizers that generate cytotoxic levels of potentially DNA-
damaging reactive oxygen species (ROS) can likewise be
combined with DDR inhibitors for additivity or synergy. Finally,
the recent development of metal complexes inhibiting PARP
activity opens up the possibility of designing dual-function
agents, combining both PARP inhibition and DNA-binding (or
ROS generation) in a single molecule.
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